Takehiko Kobayashi

Dr. Takehiko Kobayashi

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YAYuichi Adachi
Yuichi Adachi
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
TKTakehiko Kobayashi
Takehiko Kobayashi
YKYu Kurahara
Yu Kurahara
SYShiomi Yoshida
Shiomi Yoshida
KSKatsuhiro Suzuki
Katsuhiro Suzuki

1 January 2017 in Respiratory Investigation
Verified
Journal Article
Closed access
TTTaisuke Tsuji
Taisuke Tsuji
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
KTKazunobu Tachibana
Kazunobu Tachibana
YKYohei Kimura
Yohei Kimura
TKTakehiko Kobayashi
Takehiko Kobayashi
KSKatsuhiro Suzuki
Katsuhiro Suzuki

28 February 2025 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
YKYu Kurahara
Yu Kurahara
SYShiomi Yoshida
Shiomi Yoshida
AOAsami Osugi
Asami Osugi
YTYuya Tanaka
Yuya Tanaka
TKTakehiko Kobayashi
Takehiko Kobayashi
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
Background: Amikacin liposome inhalation suspension (ALIS) is key for treating refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, microbiological efficacy by subtype remains unknown. The frequency and mechanism of amikacin (AMK) resistance during ALIS administration are also unclear. Methods: We retrospectively analyzed data from refractory MAC-PD patients who received ALIS for at least 6 months as an adjunct to guideline-based therapy at the NHO Kinki Chuo Chest Medical Center. We investigated the efficacy of ALIS and analyzed gene expression and the frequency of AMK resistance. Results: We enrolled 44 patients (median age, 72.0 years): 19 (43.2%) with the noncavitary nodular bronchiectatic (NC-NB) subtype and 25 (56.8%) with the cavitary subtype. Overall, sputum culture conversion was 56.8% (25/44): 84.2% (16/19) in the NC-NB subtype and 36.0% (9/25) in the cavitary subtype (P = .001). During intermittent dosing, conversion occurred in 50.0% (9/18). In patients with C-reactive protein (CRP) ≥1 mg/dL, cavitary subtype, and clarithromycin (CLM) resistance, the risk ratio for persistently positive cultures was 10.81 (95% CI, 1.66–70.40) compared with those with CRP <1 mg/dL, NC-NB subtype, and CLM susceptibility. Of all participants, 15.9% (7/44) had isolates with AMK resistance (minimum inhibitory concentration ≥128 µg/mL), and of these 71.4% (5/7) had rrs mutations. Conclusions: Regimens that included ALIS achieved higher culture conversion in NC-NB than cavitary MAC-PD cases. High CRP levels, cavitary disease, and CLM resistance predicted persistent culture positivity. AMK resistance acquired during ALIS administration may limit treatment options for refractory MAC-PD.

1 March 2021 in Respiratory Investigation
Verified
Journal Article
Closed access
SMShojiro Minomo
Shojiro Minomo
TKTakehiko Kobayashi
Takehiko Kobayashi
KKKanako Katayama
Kanako Katayama
MRMisaki Ryuge
Misaki Ryuge
TKTomoko Kagawa
Tomoko Kagawa
KSKatsuhiro Suzuki
Katsuhiro Suzuki

1 March 2021 in Respiratory Investigation
Verified
Journal Article
Closed access
TKTakehiko Kobayashi
Takehiko Kobayashi
KTKazunari Tsuyuguchi
Kazunari Tsuyuguchi
SYShiomi Yoshida
Shiomi Yoshida
YKYohei Kimura
Yohei Kimura
TTTaisuke Tsuji
Taisuke Tsuji
KSKatsuhiro Suzuki
Katsuhiro Suzuki

15 February 2022 in Internal Medicine
Verified
Journal Article
Open access
PDF file
KKKanako Katayama
Kanako Katayama
TAToru Arai
Toru Arai
TKTakehiko Kobayashi
Takehiko Kobayashi
SSSayoko Shintani
Sayoko Shintani
NTNaoko Takeuchi
Naoko Takeuchi
YIYoshikazu Inoue
Yoshikazu Inoue
Airway-centered fibroelastosis is a distinct entity characterized by prominent airway-centered elastosis of the upper lobe with little or no pleural involvement. Little is known regarding its etiology; however, it was reported to have an idiopathic or asthma-associated etiology. We document, for the first time, 2 women (19 and 60 years old) who developed pleuroparenchymal fibroelastosis with a predominantly airway-centered distribution as a late complication (6 and 9 years later, respectively) of chemotherapy. The disease rapidly progressed following the manifestation of symptoms, and they subsequently died (3 and 2 years later, respectively). Therefore, post-chemotherapy long-term monitoring for this disease is warranted.